P
8.84
0.43 (5.11%)
| Previous Close | 8.41 |
| Open | 8.84 |
| Volume | 655 |
| Avg. Volume (3M) | 6,208 |
| Market Cap | 604,595,072 |
| Price / Earnings (Forward) | 169.49 |
| Price / Sales | 2.14 |
| Price / Book | 2.49 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | -3.98% |
| Operating Margin (TTM) | 12.66% |
| Diluted EPS (TTM) | -0.180 |
| Quarterly Revenue Growth (YOY) | 14.10% |
| Total Debt/Equity (MRQ) | 50.81% |
| Current Ratio (MRQ) | 3.77 |
| Operating Cash Flow (TTM) | -1.79 M |
| Levered Free Cash Flow (TTM) | 1.12 M |
| Return on Assets (TTM) | -0.52% |
| Return on Equity (TTM) | -5.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Pharming Group N.V. | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 5.0 |
| Average | 2.00 |
|
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 0.08% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 39.00 (Oppenheimer, 341.18%) | Buy |
| Median | 38.00 (329.86%) | |
| Low | 37.00 (HC Wainwright & Co., 318.55%) | Buy |
| Average | 38.00 (329.86%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Mar 2025 | 37.00 (318.55%) | Buy | 8.84 |
| 20 Mar 2025 | 37.00 (318.55%) | Buy | 8.93 | |
| Oppenheimer | 14 Mar 2025 | 39.00 (341.18%) | Buy | 8.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |